Because the activity of chaperone molecule must obtain energy from ATP hydrolysis, Hsp90N inhibitors disabled molecular chaperone function of Hsp90 by competitively suppressing ATP-binding to result in multiple misfolded or immature client proteins that were captured and degraded by the proteasome, cancer cells were thereby suppressed or killed. The gene discussed is HSP90AA1; the disease is cancer.